Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy).

Yabe, Daisuke; Kawamori, Dan; Seino, Yusuke; Oura, Tomonori; Takeuchi, Masakazu

Yabe, Daisuke; Kawamori, Dan; Seino, Yusuke; Oura, Tomonori; Takeuchi, Masakazu.

Afiliação

Yabe D; Department of Diabetes, Endocrinology and Metabolism, Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.
Kawamori D; Medical Education Center, Faculty of Medicine, Postgraduate Medical Training Center, Osaka University Hospital, and Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Seino Y; Department of Endocrinology, Diabetes and Metabolism, Fujita Health University, Toyoake, Japan.
Oura T; Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K, Kobe, Japan.
Takeuchi M; Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K, Kobe, Japan.

Diabetes Obes Metab ; 25(2): 398-406, 2023 02.

Article em En | MEDLINE | ID: mdl-36184780

Assuntos

Diabetes Mellitus Tipo 2; Humanos; Pessoa de Meia-Idade; Diabetes Mellitus Tipo 2/metabolismo; Hipoglicemiantes/uso terapêutico; População do Leste Asiático; Polipeptídeo Inibidor Gástrico/uso terapêutico; Fragmentos Fc das Imunoglobulinas/efeitos adversos; Proteínas Recombinantes de Fusão/efeitos adversos; Peptídeos Semelhantes ao Glucagon/uso terapêutico; Peso Corporal; Receptor do Peptídeo Semelhante ao Glucagon 1/agonistas; Resultado do Tratamento

Palavras-chave

Japan; body composition; pharmacodynamics; tirzepatide; type 2 diabetes

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 Tipo de estudo: Clinical_trials Limite: Humans / Middle aged Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google